Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularORALGeneric

BAYCOL

CERIVASTATIN SODIUM

Standard Dose
0.2MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview BAYCOL is listed in Drugs@FDA under application 020740 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CERIVASTATIN SODIUM Form and strength TABLET;ORAL - 0.2MG Sponsor BAYER PHARMS Submission history Latest submission status date: 2001-05-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview BAYCOL is listed in Drugs@FDA under application 020740 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CERIVASTATIN SODIUM Form and strength TABLET;ORAL - 0.2MG Sponsor BAYER PHARMS Submission history Latest submission status date: 2001-05-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.